written on 02.06.2014
Tags:
,

Vimizim, an Ultra-Orphan Drug and a Success Story for BioMarin

TAGS: ,

Ulrike Jahnke, Editor at Thomson Reuters, discusses how BioMarin’s Vimizim, a drug for the ultra-rare lysosomal storage disorder Morquio A syndrome, brings hope to patients with such a rare, orphan condition and is also paying off financially for BioMarin thanks the price it can ask for an ultra-orphan drug. BioMarin Pharmaceutical recently launched Vimizim (elosulfase […]

Latest Report